Effect of semaglutide treatment on liver fat content and on the acute liver fat response after high fat load in obese patients with NAFLD. - IKEM-ISS-02

Institut Klinicke A Experimentalni Mediciny0 个研究点目标入组 16 人开始时间: 2023年4月17日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•sex: male, age 18 – 70 years, BMI = 30 kg/m2, waist circumference =102 cm, hepatic fat content evaluated by MRS during screening > 5,5 %

•diabetes mellitus Type I and Type II, active malignancy, history of liver transplantation or transplantation of insulin-producing tissue, chronic treatment with corticosteroids or immunosuppressants, any other disease that, in the opinion of investigator, could endanger or disadvantage the patient if he were to participate in the clinical trial, alcohol consumption > 40 g/day, lactose intolerance, cow milk protein allergy or other intolerancies, significant change in weight (> 5 %) in the 3 months before the entering study, use of weight loss dugs, hypersensitivity to the active substance or to any auxiliary substance of investigational medicinal product, lack of legal capacity, HbA1c = 48 mmol/mol or fasting glycemia = 7 mmol/l during screening, refusal to sign informed consent, triglyceride > 4 mmol/l during screening, acute myocardial infarction, unstable angina pectoris, stroke, pulmonary embolism during 3 months before the start of study, heart failure NYHA IV., untreated thyreopathy, active hepatitis, liver cirrhosis, acute or chronic pancreatitis, chronic renal insufficiency IV-V (eGFR = 0,5 ml/s), end-stage renal failure, hemodialysis or peritoneal dialysis

发起方

Institut Klinicke A Experimentalni Mediciny